Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates

被引:0
作者
A. Sánchez
R. Blanco
机构
[1] Centro de Endocrinología,
[2] Instituto Universitario Italiano de Rosario,undefined
来源
Osteoporosis International | 2017年 / 28卷
关键词
Bisphosphonates; Complications; Drug-induced osteonecrosis of the jaw; Osteoporosis; Subtrochanteric atypical fractures; Treatment;
D O I
暂无
中图分类号
学科分类号
摘要
The aim of the study is to report the rare association of two complications of long-term treatment of osteoporosis with bisphosphonates in the same Caucasian elderly patient. A female patient of Italian descent, age 87 years, consulted in February 2013. She had a history of osteoporosis and had taken alendronate weekly for 7 years (1999–2006). Due to low back pain, an orthopedist had indicated i.v. zoledronic acid, 5 mg/year for 3 years (2006–2008). She received occasional supplements of ergocalciferol. In 2009, she suffered a fall and sustained a subtrochanteric fracture of the left femur. She was operated on and recovered uneventfully. In 2012, she consulted a dentist due to loose teeth. She underwent the removal of a molar and was given a denture. She had discomfort when using the prosthesis, and developed an ulceration in the gum of the mandible, which exposed the bone and did not heal for 2 months. After radiologic studies, the diagnosis was osteonecrosis of the jaw. She improved after surgical debridement and local and systemic antibiotics. In early 2013, laboratory tests were normal except for a slight elevation of serum PTH and CTX-I. Calcitriol 0.25 mcg/day was prescribed; after 3 months serum calcium, phosphate, PTH, and CTX-I showed no variation. Two years later, she experienced acute low back pain after a fall; MRI showed recent crushing of D12, and chronic deformities of D11 and L1. Bone densitometry of her right hip (DXA) showed a T-score of −2.3 at the femoral neck. An X-ray film of the right femur showed diffuse thickening of both cortices. She was treated with nasal calcitonin and analgesics. After the back pain subsided, she was treated with s.c. denosumab. Although the association of ONJ and AFF was known in cancer patients treated with high doses of bisphosphonates, it is very rare in patients with osteoporosis receiving these drugs at usual doses. Only three cases have been reported, all in oriental women. This appears to be the first reported case in a Caucasian woman.
引用
收藏
页码:1145 / 1147
页数:2
相关论文
共 39 条
  • [1] Fleisch H(1987)Bisphosphonates—history and experimental basis Bone 8 S23-S28
  • [2] Adler RA(2016)Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research J Bone Miner Res 31 16-35
  • [3] El-Hajj Fuleihan G(2008)[What are atypical femoral fractures?] (editorial; Spanish) Actual Osteol 8 145-149
  • [4] Bauer DC(2014)American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update J Oral Maxillofac Surg 72 1938-1956
  • [5] Sánchez A(2016)Healing time and complications in operatively treated atypical femur fractures associated with bisphosphonate use: a multicenter retrospective cohort J Orthop Trauma 30 177-181
  • [6] Ruggiero SL(2014)Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 29 1-23
  • [7] Dodson TB(2014)Gender related difference in the risk of bisphosphonate associated atypical femoral fracture and osteonecrosis of the jaw (letter) Ann Rheum Dis 73 1594-2961
  • [8] Fantasia J(2011)Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw (review) Osteoporos Int 22 2951-23
  • [9] Bogdan Y(2015)Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus J Bone Miner Res 30 3-E726
  • [10] Tornetta P(2013)Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis J Clin Endocrinol Metab 98 E723-160